Trinity Biotech PLC
NASDAQ:TRIB

Watchlist Manager
Trinity Biotech PLC Logo
Trinity Biotech PLC
NASDAQ:TRIB
Watchlist
Price: 0.81 USD -2.11% Market Closed
Market Cap: 7.7m USD
Have any thoughts about
Trinity Biotech PLC?
Write Note

Trinity Biotech PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Trinity Biotech PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Trinity Biotech PLC
NASDAQ:TRIB
Additional Paid In Capital
$57.5m
CAGR 3-Years
53%
CAGR 5-Years
29%
CAGR 10-Years
17%
Medtronic PLC
NYSE:MDT
Additional Paid In Capital
$20.8B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
STERIS plc
NYSE:STE
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Trinity Biotech PLC
Glance View

Market Cap
7.7m USD
Industry
Health Care

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.

TRIB Intrinsic Value
8.18 USD
Undervaluation 90%
Intrinsic Value
Price

See Also

What is Trinity Biotech PLC's Additional Paid In Capital?
Additional Paid In Capital
57.5m USD

Based on the financial report for Sep 30, 2024, Trinity Biotech PLC's Additional Paid In Capital amounts to 57.5m USD.

What is Trinity Biotech PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
17%

Over the last year, the Additional Paid In Capital growth was 23%. The average annual Additional Paid In Capital growth rates for Trinity Biotech PLC have been 53% over the past three years , 29% over the past five years , and 17% over the past ten years .

Back to Top